-+ 0.00%
-+ 0.00%
-+ 0.00%

GU Ventures portfolio firm Epicyt Pharma reports positive first-in-human BAFA trial results

PUBT·09/16/2026 07:54:26
Listen to the news
GU Ventures portfolio firm Epicyt Pharma reports positive first-in-human BAFA trial results
  • GU Ventures portfolio company Epicyt Pharma reported positive Phase 1/2a first-in-human results for BAFA in gastric bypass patients.
  • Trial met key signals on calcium balance, including a statistically significant reduction in urinary calcium excretion.
  • BAFA is an oral glycolate-butyric acid combination, positioned to improve calcium absorption post-RYGB, reducing long-term fracture risk.
  • Epicyt plans to advance BAFA into the next stage of clinical development.
  • Epicyt estimates 3.5 million EU and US patients have post-surgery calcium imbalance; it projects a EUR 1.4 billion market by 2035.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.